Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting

Thorax

Volumn 68, Issue 3, 2013, Pages 247-255

  Mandalakas, Anna M ^a,b,c   Hesseling, Anneke C ^c   Gie, Robert P ^c   Schaaf, H S ^c   Marais, Ben J ^d,e   Sinanovic, Edina ^f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e UNIVERSITY OF STELLENBOSCH   (South Africa)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC TEST ACCURACY STUDY; ECONOMIC EVALUATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE COST; HUMAN; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; MEDICAL DECISION MAKING; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84873724994     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2011-200933     Document Type: Article

References (44)

1. Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004;8:392-402.
2. Mahairas GG, Sabo PJ, Hickey MJ, et al. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996;178:1274-82.
3. Harboe M, Oettinger T, Wiker HG, et al. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun 1996;64:16-22.
4. Mandalakas AM, Detjen AK, Hesseling AC, et al. Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2011;15:1018-32.
5. Smieja M, Marchetti C, Cook D, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 1999:CD001363.
6. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union against tuberculosis Committee on prophylaxis. Bull World Health Organ 1982;60:555-64.
7. Curry FJ. Prophylactic effect of isoniazid in young tuberculin reactors. N Engl J Med 1967;277:562-7.
8. Hsu KH. Isoniazid in the prevention and treatment of tuberculosis. A 20-year study of the effectiveness in children. JAMA 1974;229:528-33.
9. Claessens NJ, Gausi FF, Meijnen S, et al. Screening childhood contacts of patients with smear-positive pulmonary tuberculosis in Malawi. Int J Tuberc Lung Dis 2002;6:362-4.
10. Guwatudde D, Nakakeeto M, Jones-Lopez EC, et al. Tuberculosis in household contacts of infectious cases in Kampala, Uganda. Am J Epidemiol 2003;158:887-98.
11. Van Wyk SS, Hamade H, Hesseling AC, et al. Recording isoniazid preventive therapy delivery to children: operational challenges. Int J Tuberc Lung Dis 2010;14:650-3.
12. Marais BJ, van Zyl S, Schaaf HS, et al. Adherence to isoniazid preventive chemotherapy: a prospective community based study. Arch Dis Child 2006;91:762-5.
13. Schaaf HS, Marais BJ, Whitelaw A, et al. Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases. BMC Infect Dis 2007;7:140.
14. WHO. Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. Geneva: WHO, 2006. Report No. WHO/HTM/TB/2006.371.
15. Weinstein M, Siegel J, Gold M, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8.
16. Wu SS, Chao CS, Vargas JH, et al. Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. Transplantation 2007;84:173-9.
17. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-18.
18. Palusci VJ, O'Hare D, Lawrence RM. Hepatotoxicity and transaminase measurement during isoniazid chemoprophylaxis in children. Pediatr Infect Dis J 1995;14:144-8.
19. Beyers N, Gie RP, Schaaf HS, et al. A prospective evaluation of children under the age of 5 years living in the same household as adults with recently diagnosed pulmonary tuberculosis. Int J Tuberc Lung Dis 1997;1:38-43.
20. Kruk A, Gie RP, Schaaf HS, et al. Symptom-based screening of child tuberculosis contacts: improved feasibility in resource-limited settings. Pediatrics 2008;121: e1646-52.
21. Lienhardt C, Sillah J, Fielding K, et al. Risk factors for tuberculosis infection in children in contact with infectious tuberculosis cases in the Gambia, West Africa. Pediatrics 2003;111:e608-14.
22. Mandalakas A, Kirchner HL, Lombard C, et al. Well quantified TB exposure is a reliable surrogate measure of M.tb infection in children. Int J Tuberc Lung Dis 2012. http://dx.doi.org/10.5588/ijtld.12.0027.
23. Mandalakas AM, Detjen AK, Benedetti A, et al. Interferon-gamma Release Assays for the Diagnosis of LTBI and Active TB In Children - A Systematic Review and Meta-analysis. Geneva: World Health Organization, 2010.
24. van Zyl S, Marais BJ, Hesseling AC, et al. Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. Int J Tuberc Lung Dis 2006;10:13-18.
25. Alperstein G, Morgan KR, Mills K, et al. Compliance with anti-tuberculosis preventive therapy among 6-year-old children. Aust N Z J Public Health 1998;22:210-13.
26. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979;119:827-30.
27. Debre R, Perdrizet S, Lotte A, et al. Isoniazid chemoprophylaxis of latent primary tuberculosis: in five trial centres in France from 1959 to 1969. Int J Epidemiol 1973;2:153-60.
28. Maree F, Hesseling AC, Schaaf HS, et al. Absence of an association between Mycobacterium tuberculosis genotype and clinical features in children with tuberculous meningitis. Pediatr Infect Dis J 2007;26:13-18.
29. van Well GT, Paes BF, Terwee CB, et al. Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the western cape of South Africa. Pediatrics 2009;123:e1-8.
30. Kritzinger F, den Boon S, Verver S, et al. No decrease in annual risk of tuberculosis infection in endemic area in Cape Town, South Africa. Trop Med Int Health 2009;14:136-42.
31. ASSA. AIDS and Demographic Model of the Actuarial Society of South Africa. 2003. http://www.assa.org.za (accessed 27 May 2012).
32. Marais BJ, Gie RP, Schaaf HS, et al. The spectrum of disease in children treated for tuberculosis in a highly endemic area. Int J Tuberc Lung Dis 2006;10:732-8.
33. Sinanovic E, Moodley J, Barone M, et al. The potential cost-effectiveness of adding a human papillomavirus to the cervical cancer screening programme in South Africa. Vaccine. 2009;27:6196-202.
34. van Wyk S, Hamade H, Hesseling A, et al. Recording practices of isoniazid preventive therapy delivery to children in a high-burden tuberculosis setting: operational challenges. Int J Tuberc Lung Dis 2010;14:650-3.
35. Diel R, Nienhaus A, Lange C, et al. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J 2006;28:35-44.
36. Diel R, Nienhaus A, Loddenkemper R. Cost-effectiveness of interferon-{gamma} release assay screening for latent tuberculosis infection treatment in Germany. Chest 2007;131:1424-34.
37. Wrighton-Smith P, Zellweger JP. Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J 2006;28:45-50.
38. WHO. Use of Tuberculosis Interferon-gamma Release Assays (IGRAs) in Low- and Middle Income Countries: Policy Statement. Geneva: World Health Organization, 2011.
39. Diel R, Nienhaus A, Schaberg T. Cost-effectiveness of isoniazid chemoprevention in close contacts. Eur Respir J 2005;26:465-73.
40. Dasgupta K, Menzies D. Cost-effectiveness of tuberculosis control strategies among immigrants and refugees. Eur Respir J 2005;25:1107-16.
41. Dasgupta K, Schwartzman K, Marchand R, et al. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations. Am J Respir Crit Care Med 2000;162:2079-86.
42. WHO. Macroeconomics and Health: Investing in Health for Economic Development: Report on the Commission on Macroeconomics and Health. Geneva: World Health Organization, 2001.
43. WorldBank. World Development Indicators Database. Washington: World Bank, 2006.
44. World Health Organization. Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Geneva, Switzerland: World Health Organization, 2011.